Form 4: HeartBeam President Granted 61,932 Stock Options

HeartBeam, Inc. President and Director Branislav Vajdic was granted 61,932 stock options with an exercise price of $1.45 per share.

Summary

• Branislav Vajdic, President, Director, and 10% Owner of HeartBeam, Inc. (BEAT), was granted 61,932 options to purchase common stock.
• The options have an exercise price of $1.45 per share.
• These options were granted on February 9, 2026, and are part of the Company's 2022 Equity Incentive Plan.
• One half of the total options (30,966 shares) will vest on March 31, 2026, which is the three-month anniversary of the vesting commencement date.
• The remaining half of the options (30,966 shares) will vest on June 30, 2026, the six-month anniversary of the vesting commencement date.
• The vesting commencement date for these options is January 1, 2026.
• The options have an expiration date of January 1, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive incentives with shareholder value, but it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a key executive like the President aligns management's interests with long-term shareholder value creation.
• The options are issued from an existing equity incentive plan, indicating a structured approach to executive compensation.

Negatives

• The exercise price of $1.45 per share is a fixed price, meaning the options will only have intrinsic value if the stock price rises above this level.

Risks

• No specific risks were mentioned in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting and expiration dates of the options.

Management Comments

• The options have been issued from the Company's 2022 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to executives are a standard practice across the medical technology and healthcare sectors, aiming to incentivize long-term performance and align leadership interests with shareholder returns. Such grants are common for companies like HeartBeam, which operates in the medical device space, as they seek to retain key talent and drive innovation.

Comparison to Industry Standards

• The grant of 61,932 options to a President and Director is a typical size for an executive in a small to mid-cap medical technology company, comparable to grants seen at emerging biotech firms or medical device startups.
• The vesting schedule, with a portion vesting at 3 and 6 months, is relatively short-term compared to more common multi-year annual vesting schedules (e.g., 25% per year over four years). This could indicate a focus on near-term performance milestones or a specific retention strategy.
• The exercise price of $1.45 is set at the market price on the grant date, which is standard practice for incentive stock options, ensuring that the executive benefits only if the company's stock appreciates.

Related Party Transactions

• The grant of options to Branislav Vajdic, who is a Director, President, and 10% Owner, constitutes a related party transaction as it involves compensation to a key insider.

Stakeholder Impact

• Shareholders: The grant aims to incentivize the President to increase shareholder value. However, it also represents potential future dilution if options are exercised.
• Employees: This filing specifically relates to executive compensation and does not directly impact other employees, though it reflects the company's overall compensation strategy.
• Management: The options provide a significant incentive for the President to drive company performance and stock price appreciation.

Next Steps

• One half of the granted options will vest on March 31, 2026.
• The remaining half of the granted options will vest on June 30, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction related to executive compensation. While it aligns management incentives, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and await more substantive corporate updates.

Keywords

HeartBeam, BEAT, Stock Options, Form 4, Insider Transaction, Equity Incentive Plan, Executive Compensation, Branislav Vajdic, Director, President